[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"splenectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:splenectomy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,62,91,109,146,174,208,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":46,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100567703","stanford-program-to-accelerate-robotic-childrens-surgery-100567703",false,"NCT06671639","Stanford Program to Accelerate Robotic Children's Surgery","SPARCS","Inclusion Criteria:\n\n1. Subject is between 6 - 21 years of age (weighing at least 15 kilograms)\n2. Subject clinically diagnosed with a medical condition for which one of the study procedures is appropriate therapy and selected as the treatment of choice by the guardian and surgeon.\n3. Subject without previous treatment using a robotic surgery device\n4. Subject or their guardian is willing and able to provide written informed consent\n5. Subject or their guardian is willing and able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Subject with uncorrected coagulopathy\n2. Subject has clinical requirement for primary open operative procedure\n3. Subject is ASA 4 or 5 status\n4. Subject is contraindicated for general anesthesia or surgery\n5. Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent\n6. Subject is pregnant or suspected to be pregnant","ALL","6 Years","21 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to provide additional data to confirm safety and performance of the da Vinci Xi Surgical System in a human clinical setting. This pilot study is intended to provide an initial assessment to evaluate the feasibility, safety, and effectiveness for the utilization of the da Vinci Xi on pediatric and adolescent patients. This clinical trial will be conducted under the auspices of Stanford University's IRB approval.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Sleeve Gastrectomy","Cholecystectomy","Splenectomy","Hysterectomy","Endometriosis","Ureteral Re-implant","Cervical and Thoracic Tracheoplasty","Thymectomy","Lobectomy\u002FWedge Lung Resection","Lung Segmentectomy","Bronchoplasty","Endoscopic Laryngeal\u002FPharyngeal Suturing","Vocal Feminization","Laryngeal Cleft Repair","Endolaryngeal Adjacent Tissue Transfer","Pharyngoplasty","Ileocolonic Resections","Laryngoplasty","Proctectomy With Ileal Pouch-Anal Anastomosis",[47,48],"Robotic Surgery","Pediatric Robotic Surgery","RECRUITING","2026-04-24",{"date":52,"type":53},"2026-04-30","ACTUAL",{"date":55,"type":53},"2025-08-01",{"date":57,"type":21},"2028-02-28",{"name":59,"class":60},"Stanford University","OTHER",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":61},"100628431","efficacy-of-apixaban-in-the-treatment-of-portal-vein-thrombosis-occurring-more-than-one-year-after-ls-100628431","NCT07461545","Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy","Inclusion Criteria:\n\n1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.\n2. Splenomegaly with secondary hypersplenism.\n3. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.\n4. Underwent laparoscopic splenectomy at our center.\n5. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.\n6. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3\n7. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.\n8. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.\n9. Developed portal vein thrombosis after 12 months post-surgery.\n10. Provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hepatocellular carcinoma or any other malignancy.\n2. Hypercoagulable state other than the liver disease related.\n3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n4. Portal hypertension bleeding .\n5. Child - Pugh C\n6. Recent peptic ulcer disease\n7. History of Hemorrhagic stroke\n8. Pregnancy.\n9. Uncontrolled Hypertension\n10. Human immunodeficiency virus (HIV) infection","18 Years",{"count":71,"type":21},20,[24],"The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.",[75,29,76,77],"Cirrhosis","Portal Vein Thrombosis","Hypertension, Portal",[75,76,79,80,29,81],"Portal Hypertension","Apixaban","Laparoscopy","2026-03-25",{"date":84,"type":53},"2026-03-31",{"date":86,"type":21},"2026-04-01",{"date":88,"type":21},"2027-09-30",{"name":90,"class":60},"Northern Jiangsu People's Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":108,"locationsCount":61},"100628430","efficacy-of-apixaban-in-treating-portal-vein-thrombosis-occurring-more-than-one-year-after-lsd-100628430","NCT07461532","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD","Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After Laparoscopic Splenectomy and Azygoportal Disconnection","Inclusion Criteria:\n\n1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.\n2. Portal hypertension bleeding .\n3. Splenomegaly with secondary hypersplenism.\n4. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.\n5. Underwent laparoscopic splenectomy at our center.\n6. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.\n7. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3\n8. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.\n9. Had no imaging evidence (Doppler ultrasound or CT) of portal vein thrombosis during postoperative months 6 to 12.\n10. Developed portal vein thrombosis after 12 months post-surgery.\n11. Provided informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Hepatocellular carcinoma or any other malignancy.\n2. Hypercoagulable state other than the liver disease related.\n3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.\n4. Child - Pugh C\n5. Recent peptic ulcer disease\n6. History of Hemorrhagic stroke\n7. Pregnancy.\n8. Uncontrolled Hypertension\n9. Human immunodeficiency virus (HIV) infection",{"count":71,"type":21},[24],"The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.",[75,29,76,77],[75,76,79,80,29,81,103,104],"Hypersplenism","Azygoportal disconnection",{"date":84,"type":53},{"date":86,"type":21},{"date":88,"type":21},{"name":90,"class":60},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100620228","evaluation-of-the-effectiveness-of-an-educational-intervention-in-splenectomized-patients-100620228","NCT07354893","Evaluation of the Effectiveness of an Educational Intervention in Splenectomized Patients","Evaluation of an Educational Intervention on Knowledge and Awareness of Infectious Risk in Splenectomized Patients and on Their Satisfaction With Vaccination Management in an Intra-hospital Outpatient Setting.","SPLE-VAC","Inclusion Criteria:\n\n* Adult patients (≥18 years old)\n* Patients splenectomized at FPG for whom a vaccination consultation is requested during hospitalization\n* Patients who provide signed informed consent to participate in the study and for the processing of personal data for research purposes\n\nExclusion Criteria:\n\n* Minor patients\n* Lack of signed informed consent for participation in the study and for the processing of personal data for research purposes\n* Patients splenectomized at other healthcare facilities",{"count":118,"type":21},100,"24 Months","OBSERVATIONAL","The absence or dysfunction of the spleen is associated with a substantially increased risk of invasive infections that may rapidly progress to fulminant sepsis, including overwhelming post-splenectomy infection (OPSI), a medical emergency with high mortality. Although the risk is greatest in the first two years after splenectomy, it persists lifelong. Preventing infections in patients with anatomical or functional asplenia requires an integrated strategy that includes patient education, early recognition of symptoms, behavioral measures, antibiotic prophylaxis when indicated, and vaccination.\n\nPost-splenectomy immunization has been shown to reduce OPSI incidence. Regional and international guidelines recommend vaccination against pneumococcus, Haemophilus influenzae type b, meningococcus (B and ACWY), herpes zoster, diphtheria-tetanus-pertussis, measles-mumps-rubella-varicella, and annual influenza. However, adherence to these recommendations is frequently suboptimal, often due to limited awareness among patients and healthcare professionals.\n\nThis study involves the intra-hospital vaccination team providing structured vaccination consultations to splenectomized patients hospitalized at the Fondazione Policlinico Universitario \"A. Gemelli\" IRCCS. During ward consultations, patients receive an educational intervention on asplenia-related infectious risks and preventive measures, supported by standardized informational materials. Effectiveness is evaluated using a pre-post questionnaire assessing knowledge and awareness. Patients completing the vaccination pathway at the outpatient clinic also complete a questionnaire assessing their experience with vaccination management in an intra-hospital setting.",[123,29,124,125],"Splenectomized Patients","Splenectomy; Status","Asplenia",[127,128,129,130,131,132,133,134,135],"OPSI","infection risk","Infection Prevention","Preventive measures","Vaccination","asplenia","splenectomy","splenectomized patients","post splenectomy infections","2026-01-29",{"date":138,"type":53},"2026-02-02",{"date":140,"type":53},"2026-01-13",{"date":142,"type":21},"2028-01-13",{"name":144,"class":60},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",2,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":61},"100375298","phase-3-research-trial-assessing-the-immunogenicity-and-safety-of-three-meningococcal-b-vaccine-strategies-among-patients-with-asplenia-100375298","NCT04166656","Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","Multicenter, Randomized, Phase III, Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia","SPLEMENGO","Inclusion Criteria:\n\n1. Male or female, \\>=18 to \\\u003C=75 years old.\n2. Asplenic patient (for at least 2 weeks) with Howell Jolly bodies visible on blood film\n3. Splenectomy confirmed by consultation and\u002For hospitalization report or the ultrasound if it has been performed during the routine follow-up\n4. Women of childbearing age must have an effective contraception during the first 9 months of the study.\n5. Participants must give written consent prior to any trial procedure\n6. Participants must be covered by social security regimen or equivalent.\n7. Participants will be followed during the 4 years from the inclusion visit.\n\nExclusion Criteria:\n\n1. History of meningococcal vaccination B.\n2. History of anaphylaxis post vaccination.\n3. Known allergy to any components (active substances or excipients) of both vaccines.\n4. Patients who cannot stop antibiotics 3 days before blood collection.\n5. Participants who have received any another vaccines within 4 weeks prior to immunization or who are planning to receive any vaccine within the first 7 months of the study (except the meningococcal ACWY vaccine, the anti-pneumococcal vaccine, the Haemophilus influenzae type B vaccine, the anti-Covid-19 vaccine), annual influenza vaccination which is permitted 2 weeks before and after each vaccination visit of the study and then allowed at any time during the study follow up).\n6. Parenteral Ig within the 3 months prior to VS or planned during the study.\n7. Chemotherapy agents within 6 months prior M0 or planning to take any during the study.\n8. Steroids (\\> 10mg\u002Fday; \\> 14 days) within the month preceding M0 or planning to take any during the study.\n9. Any pathology or condition that may impair the immune response, apart from splenectomy: immunosuppressive therapy in progress or in the 6 months prior to inclusion, hematopoietic stem cells allo \u002F autograft, primary immunodeficiency, nephrotic syndrome, evolutive cancer, cirrhosis, known infection to HIV;\n10. Thrombocytopenia or any coagulation disorder contra-indicating intramuscularly injections.\n11. Pregnancy, breastfeeding or positive pregnancy test up to 7 months after inclusion.\n12. Severe acute febrile illness within the week before inclusion.\n13. Registration for any other clinical trial throughout the trial period except observational study.","75 Years",{"count":156,"type":21},84,[158],"PHASE3","The purpose of the study is to evaluate the immunological response and tolerance of 3 vaccine strategies against meningococcus B, a potentially fatal invasive infection.",[29],[162,163,164],"Meningococcal B vaccine","vaccine strategies","splenectomized individuals","2025-11-17",{"date":167,"type":53},"2025-11-20",{"date":169,"type":53},"2022-09-15",{"date":171,"type":21},"2028-10",{"name":173,"class":60},"Assistance Publique - Hôpitaux de Paris",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100548227","physiology-and-pathologies-linked-to-human-splenic-function--direct-and-ex-vivo-perfusion-explorations-100548227","NCT06418256","Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations","SPLEENVIVO","Inclusion Criteria:\n\n* Adult patients\n* Patient requiring left splenopancreectomy or planned splenectomy regardless of the method or indication\n\nExclusion Criteria:\n\n\\- The patient notified his doctor of his refusal to recover his spleen and blood volume",{"count":118,"type":21},"Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating cells and to trigger an innate and adaptive response in response to these anomalies, the spleen plays a central role in several diseases affecting blood cells, directly or indirectly. The analysis of the splenic clearance of abnormal cells during ex-vivo perfusions made it possible to clarify the pathogenesis of malaria and the role of the spleen in the adaptive immune response. The study's investigative team wishes to extend these explorations to other human diseases in which the spleen is involved, and to evaluate the preventive or curative potential of substances that can modify the perception of blood cells by the spleen (e.g. monoclonal antibodies directed against circulating cells, among other options).",[29],[185,186,187,188,189,190,191,192,193,194,195,196,197,198],"Spleen","Human splenic physiology","Splenic clearance","Splenic filtration mechanisms","Perfusion experiments","Role of the spleen in the adaptive immune response","Genetic spleen mechanisms","Blood","Erythrocytes","Leukocytes","Lymphocytes","Malaria","Sickle cell disease","Hereditary spherocytosis","2025-09-08",{"date":201,"type":53},"2025-09-15",{"date":203,"type":53},"2016-10-16",{"date":205,"type":21},"2031-10-16",{"name":173,"class":60},5,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":227,"overallStatus":237,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":61},"100582913","study-of-the-prevalence-of-acid-sphingomyelinase-deficiencyniemann-pick-ab-and-b-disease-in-patients-with-diffuse-interstitial-lung-disease-100582913","NCT06869499","Study of the Prevalence of Acid Sphingomyelinase Deficiency\u002FNiemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","Niemann-PID: Study of the Prevalence of Acid Sphingomyelinase Deficiency\u002FNiemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","Niemann-PID","Inclusion Criteria:\n\n1. Interstitial lung disease with ground-glass lesions on a chest CT scan certified by a pneumologist\u002Fradiologist or internist.\n2. At least one of the following criteria :\n\n   * Splenomegaly (palpable spleen or craniocaudal length ≥ 13 cm)\n   * Splenectomy\n   * Thrombocytopenia (platelets \\\u003C 150 G\u002FL)\n   * Low HDL-cholesterol (\\\u003C0.4 g\u002Fl or 1.03 mmol\u002Fl)\n   * Notion of parental consanguinity\n3. Have given their written informed consent, in accordance with regulations.\n4. Affiliated to the social security system or entitled beneficiary (excluding AME).\n\nExclusion Criteria:\n\n1. Inability to understand the information provided.\n2. Under guardianship, curatorship or legal protection.\n3. Under restraint or deprived of liberty by judicial or administrative decision.","15 Years","60 Years",{"count":219,"type":21},200,[24],"The goal of this clinical trial is to optimise and facilitate screening for Acid SphingoMyelinase Deficiency (ASMD) disease, by evaluating acid sphingomyelinase activity and, where appropriate, LysoSM levels in a cohort of 200 participants with diffuse interstitial lund disease (ILD) at risk of developing ASMD disease.\n\nILD is common in the general population, so in order to limit the number of differential diagnoses, the population to be studied will be restricted to participants aged between 15 years and 3 months and 60 years, with ILD plus ground-glass opacities on chest CT scan certified by a pulmonologist\u002Fradiologist or internist, AND splenomegaly or splenectomy, and\u002For thrombocytopenia, and\u002For low HDL cholesterol, and\u002For parental consanguinity which increase the sensitivity of ASMD screening.\n\nIn this clinical trail, two procedures are added, participants will be asked for :\n\n* a blood sample to measure the acid sphingomyelinase enzyme activity and LysoSM, if required.\n* a follow-up visit at 6 months",[223,29,224,225,226],"Splenomegaly","Thrombopenia","Interstitial Lung Disease (ILD)","Hypocholesterolemia",[228,229,230,231,232,233,234,235,236],"Acid sphingomyelinase deficiency","Ground glass lesions","Niemann Pick A\u002FB, B","lysoSM","smpd1","splenomegaly","interstitial lung disease","screening","acid sphingomyelinase","NOT_YET_RECRUITING","2025-05-14",{"date":240,"type":53},"2025-05-18",{"date":242,"type":21},"2025-05",{"date":244,"type":21},"2029-03-01",{"name":246,"class":60},"Wladimir MAUHIN, Dr",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":253,"sex":16,"minAge":69,"maxAge":217,"enrollmentInfo":254,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":61},"100362351","evaluation-of-immune-status-before-and-after-splenectomy-in-immune-thrombocytopenia-patients-100362351","NCT03998059","Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia Patients","Inclusion Criteria:\n\n* Aged 18 to 60 years old, male or female;\n* Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)\n* Needed splenectomy;\n* People who are willing to sign the informed consent voluntarily and follow the research program.\n\nExclusion Criteria:\n\n* Secondary thrombocytopenic purpura;\n* Patients with poor compliance;\n* Researchers believe that patients should not participate in the test of any other condition.",true,{"count":255,"type":21},50,"Evaluation of immune status before and after splenectomy in immune thrombocytopenia patients.",[258,29],"Thrombocytopenia",[258,133],"2025-02-20",{"date":262,"type":53},"2025-02-24",{"date":264,"type":53},"2019-01-23",{"date":266,"type":21},"2025-07-23",{"name":268,"class":60},"Institute of Hematology & Blood Diseases Hospital, China"]